Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility study

• Conditions: Liver Cancer; Primary Liver Cell Carcinoma; 10019654; 10003816; 10019815

• Registration Number: NL-OMON47991
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 35

Inclusion Criteria

- Patients diagnosed with autoimmune hepatitis
- Age: 18 years or older
- Written informed-consent

Exclusion Criteria

- Patients with current use of immune suppressive agents/medication, not other
specified
- Patients with an immunocompromised medical condition, not other specified
- Patients who refuse to participate in the study (refusing blood donation)
- Patients that for medical reasons are judged unfit to donate blood by the
treating physicians

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>(a series of) TCR(s) that have a high affinity and show exclusive recognition<br /><br>of liver antigens when presented by HLA molecules of liver transplant<br /><br>recipients, and that can safely be used in a future clinical trial of adoptive<br /><br>T cell therapy for HCC recurrence after LTx.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A.</p><br>